Blog

The Phase 1b study will evaluate LV UNO in unresectable cutaneous or subcutaneous histologically con...

LV UNO in combination with anti-rPD-L1 resulted in prolonged survival and doubled the tumor growth i...

Submitted abstracts selected for the annual meeting are scheduled to be released to SITC registrants...

Ongoing Phase 1a first-in-human clinical trial continues to demonstrate proof of concept for the UNO...

Company to host an event featuring key opinion leaders (KOLs) on Friday, May 31st in Chicago to high...

No dose limiting toxicities were reported in the first cohort of ultra-high concentration of nitric ...

First-in-human Phase 1 study demonstrates early clinical proof of concept

UNO therapy results in a more immunogenic tumor microenvironment (TME) as well as a systemic respons...

50,000 or 100,000 ppm UNO alone or in combination with anti-mCTLA-4 more than tripled antigen specif...

GARDEN CITY, NY and HAMILTON, BERMUDA, October 4, 2023 – Beyond Cancer, Ltd., an affiliate of Beyond...